19-Protein Panel Predicts ALS Conversion Up to 5 Years Ahead

3 articles · Updated · National Institutes of Health (NIH) (.gov) · Jul 27

A longitudinal study of 516 plasma samples from 137 people found a 19-protein blood panel predicted when symptom-free ALS gene carriers would convert to clinically manifest disease across 0.5- to 5-year windows.
Cross-validated accuracy ranged from 0.80 to 0.89 AUC, and the panel estimated time to phenoconversion with a 1.6-year mean absolute error—beating NEFL alone except for the final 6 months before conversion.
Researchers identified 92 proteins that changed before conversion, with signals tied to skeletal muscle, extracellular matrix, neurofilament and TNF-related pathways; proteins such as CA3 and EDA2R rose years earlier, while NEFL spiked closer to onset.
UK Biobank data partly replicated the findings, confirming pre-symptomatic increases in several proteins and showing a multi-protein panel still outperformed NEFL alone, though replication was limited by cross-sectional data and estimated onset timing.
The results could help ALS prevention trials enroll carriers at highest near-term risk, addressing a major barrier in testing interventions before symptoms appear.

Sources

National Institutes of Health (NIH) (.gov)27d ago

Blood Biomarkers Predict ALS Symptom Onset Within Two Years

Technology Networks28d ago

Blood Biomarkers Predict ALS Onset | Technology Networks

studyfinds.com25d ago

Can Blood Tests Predict ALS Before It Strikes? Here's What Scientists Found

5 Sources

Could a new blood test predict the exact year a silent genetic mutation triggers a deadly neurodegenerative disease?

Why are scientists abandoning the standard ALS biomarker for a complex 19-protein signature to predict symptom onset?

If a test reveals ALS symptoms will begin in six months, is the medical world truly ready to intervene?

The 19-Protein Panel That Can Forecast ALS Onset Up to Five Years Early: Clinical, Ethical, and Regulatory Implications

Overview

This report highlights a major breakthrough in ALS research: a 19-protein blood panel developed through years of tracking at-risk individuals and advanced proteomic analysis. By applying machine learning to thousands of protein measurements, scientists created a tool that can predict ALS symptom onset up to two years in advance, enabling precise enrollment in prevention trials and improving trial efficiency. The panel’s effectiveness was validated in a large, general population cohort, confirming its relevance beyond familial ALS. This innovation not only accelerates clinical research but also opens the door to earlier intervention and more accurate, non-invasive diagnosis of ALS and related neurodegenerative diseases.

...